OncoTherics is a new pharmaceutical company, focusing on the development of novel hypoxia-activated pro-drugs for the treatment of a wide range of cancers... The company was formed as a spin-out from BioStatus, to progress a novel small molecule, code-named OCT1002. The company is at an early stage but the patented technology has a unique history allowing a more rapid than usual progression through the clinical trial process. For further information, please contact us using the contact form provided on this site ...